Gsa Capital Partners LLP Vaxart, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$0.56 - $1.41 $211,971 - $533,713	-378,520 Reduced 77.49%	109,976 $142,000
Q4 2023 Feb 16, 2024	BUY	$0.57 - $0.85 $117,168 - $174,725	205,559 Added 72.65%	488,496 $278,000
Q3 2023 Nov 15, 2023	BUY	$0.69 - $0.85 $185,822 - $228,911	269,308 Added 1975.99%	282,937 $212,000
Q2 2023 Aug 14, 2023	BUY	$0.6 - $1.41 $8,177 - $19,216	13,629 New	13,629 $9,000
Q2 2021 Aug 05, 2021	SELL	$5.06 - $10.78 $97,708 - $208,161	-19,310 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$5.64 - $23.33 $50,415 - $208,546	8,939 Added 86.19%	19,310 $117,000
Q4 2020 Feb 03, 2021	BUY	$3.5 - $7.98 $36,298 - $82,760	10,371 New	10,371 $59,000

107

37.7M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $86M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.